Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Healthcare Biotechnology
Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Noxopharm Ltd > NOX BEGINS PROGRAM ON
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by ArtVandelay4on Jan 16, 2013 12:25pm
122 Views
Post# 20845464

RE: RE: RE: RE: RE: RE: RE: NOX BEGINS PROGRAM ON

RE: RE: RE: RE: RE: RE: RE: NOX BEGINS PROGRAM ON

Hi all,

I agree that it is impossible to know the true angle, if any, on this.  I personally think it is good that drilling has begun, regardless of who is paying for it.  I also have trouble believing that the new resource estimate for phase 2 will not be good news, considering the results that were release during the program - But I am not a geologist.  Regardless of all that, i have a Question.  The option with Aurizon was to spend $20 Million over 3 years to earn 50% (with resource payment).  That was July 2010, if Aurizon does not spend the full $20 Million by July 2013, is the option still available.  The point I am trying to make is that ARZ or the new owner wil not be able to spend the required further $9 M by July 2013, expecially with the hostile bid, etc. now going on - does that have any bearing on the option agreement.  Now, i am sure NOX would have the ability to extend the dates, but would they want to?

Thanks in Advance

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities